Suppose the third and fourth largest pharmaceutical companies by revenues announce a merger. Both have extensive product lines and market prescription drugs all over the world. Are the following antitrust markets:
(a) All prescription drugs.
(b) All pharmaceuticals made by "brand-name" firms-typically inventors of drugs.
(c) All pharmaceuticals made by generic firms-firms that enter and produce drugs for which patent protection has expired.
(d) All treatments for an affliction.
(e) A particular molecule.
(f) The brand-name version of a molecule.
(g) How do the following matter? (i) no legal scope for pharmacists to substitute generics for a brand-name prescription vs. mandatory substitution rules to the cheapest formulation of the same molecule; (ii) size of the cash market; (iii) size of deductibles for those covered by insurance; (iv) dispensing fees based on the value of the prescription vs. fixed dispensing fees.